The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Evogene and Unravel Biosciences are collaborating to use AI to speed the development of therapies that promote myelin sheath ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways MS medications can help slow the disease and manage symptoms.

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

Shares drop after FDA delays decision on tolebrutinib drug Late-stage trial shows drug fails to slow disability progression Analysts fret over Sanofi drug pipeline and investor confidence Dec 15 ...